## WAT: Waters Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.0% below STRENGTH zone (4.0-10.0%); PEG 6.15 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($364.87)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Waters Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026**
- Source: Yahoo Finance | 20251223T160835 | Neutral | Relevance: 100%
- Waters Corporation (NYSE:WAT) announced that CEO Udit Batra will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12th, 2026, at 2:15 PM Pacific Time. A live webcast and replay of the event will be available on the company's Investor Relations website. Waters Corporation is a global leader in analytical instruments and software, serving various scientific fields.

**2. Did Revvity’s New AI Discovery Platform (RVTY) Quietly Redefine Its Innovation Moat?**
- Source: Simply Wall Street | 20251222T112310 | Somewhat-Bullish | Relevance: 64%
- Revvity, Inc. launched Signals Xynthetica, an AI-powered platform for molecular and materials design, aiming to integrate AI directly into laboratory workflows. This move reinforces Revvity's strategy to shift towards higher-margin, software-enabled tools, offsetting pressures in legacy diagnostics and supporting recurring digital revenue. Despite the promising AI advancements, the company still faces risks from tightening reimbursement policies and pricing pressure in diagnostics, with its long-term financial health depending on a balance between AI investments and capital returns.

**3. Your 15 Assertio shares become 1 next week—here’s what happens**
- Source: Stock Titan | 20251222T210842 | Neutral | Relevance: 63%
- Assertio Holdings (ASRT) announced a 1-for-15 reverse stock split, effective December 26, 2025, to maintain its Nasdaq listing. This action converts every fifteen existing shares into one new share, with proportionate adjustments to convertible senior notes and equity incentive plans. Fractional shares will be paid in cash based on the December 24, 2025 closing price.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $415 | $385 | +8% |
| 2025-12-10 | Wolfe Research | $480 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $423 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-10 | Wolfe Research | up | Outperform |
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (+3.3%)
- Blackrock Inc.: 10.2% (-7.6%)
- Fundsmith LLP: 6.6% (+9.6%)
- Massachusetts Financ: 4.5% (+44.3%)
- State Street Corpora: 4.5% (+0.1%)

### Key Risks

1. Valuation stretched: PEG 6.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 6.15 signals overvaluation risk, limited margin of safety. Forward P/E 26.8x stretched relative to 9% growth. Quality metrics strong (ROE 33%, ROA 12%, margin 21%). Analyst sentiment positive (1 raises, avg +8%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.8B |
| Beta | 1.16 |
| 52W Range | $275.05 - $423.56 |
| Short Interest | 5.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 6.15 |
| Forward P/E | 26.8 |
| Current P/E | 29.2 |
| YoY Growth | 9.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -2.0% to -3.0% (-1.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.0pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.13x) but short-term weakness (below SMA20). MACD histogram bearish (-2.76), momentum weakening. RSI neutral at 51. Elevated volume (1.5x 20MA), institutional activity likely. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.99% (CS: 23) | Weak |
| RSI_14 | 50.6 | Neutral |
| MACD Histogram | -2.76 | Bearish |
| vs SMA20 | 0.980x | Below |
| vs SMA50 | 1.026x | Above |
| vs SMA200 | 1.130x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $383.29
- **Stop Loss:** $364.87 (4.8% risk)
- **Target:** $401.71 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 65
- **Position Value:** $24,913.85
- **Portfolio %:** 24.91%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-11 (Est: $4.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.22 | $3.40 | +5.5% |
| 2025Q2 | $2.94 | $2.95 | +0.3% |
| 2025Q1 | $2.22 | $2.25 | +1.2% |
| 2024Q4 | $4.03 | $4.10 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*